Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial - Report - MDSpire

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • By

  • Ignacio Melero

  • Bernhard Reis

  • Corinne Rusterholz

  • Alexandra Epp

  • Nicole A. Kratochwil

  • Chun Wu

  • Michael Hettich

  • Georgios Kazantzidis

  • Natascha Rieder

  • Petra C. Schwalie

  • Solveig Badillo

  • Nadine Kumpesa

  • Andreas Thommen

  • Danielle J. Vugts

  • Victor Moreno

  • Julia Lostes Bardaji

  • Eduardo Castanon Alvarez

  • Carlos E. de Andrea

  • Iben Spanggaard

  • Dae Ho Lee

  • James Spicer

  • Fiona Thistlethwaite

  • Do-Youn Oh

  • Antoine Hollebecque

  • Olivera Cirovic

  • Stefan N. Symeonides

  • May 1, 2026

  • 0 min

Share

Clinical Report: Evaluation of RO7300490 in Advanced Solid Tumors

Overview

{'treatment_related_adverse_events': 'Specify types and grades.'}

Background

{'previous_cd40_agonists': 'Add details on challenges faced.'}

Data Highlights

{'table_format': 'Ensure correct formatting and completeness.'}

Key Findings

{'total_patients': 'Include total number of patients for TRAEs.'}

Clinical Implications

{'limitations': 'Discuss considerations for clinicians.'}

Conclusion

{'further_studies': 'Specify aspects of efficacy needing confirmation.'}

References

  1. Blood Cancer Journal, 2021 -- A Phase 1b Study on Dose Escalation and Expansion of the BET Inhibitor RO6870810 in Patients with Advanced Multiple Myeloma
  2. The ASCO Post, 2018 -- Study Findings on Novel Agents in Neoplastic Hematology
  3. Blood Cancer Journal, 2025 -- Combination of Glofitamab and Tislelizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Pilot Study at a Single Institution
  4. The ASCO Post, 2021 -- Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
  5. Nature Cancer, 2023 -- Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors
  6. Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin
  7. CE NCCN GUIDELINES® INSIGHTS Management of Immunot

Original Source(s)

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

  • by Ignacio Melero, Bernhard Reis, Corinne Rusterholz, Alexandra Epp, Nicole A. Kratochwil, Chun Wu, Michael Hettich, Georgios Kazantzidis, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Julia Lostes Bardaji, Eduardo Castanon Alvarez, Carlos E. de Andrea, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Olivera Cirovic, Stefan N. Symeonides

  • May 1, 2026

Related Content

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?